Even so, it will be interesting to see if Indianapolis-based Lilly will be able to snag some of Merck's share, here
. . . .The drug is designed to be taken once a day to reduce a patient’s blood sugar levels by blocking glucose reabsorption in the kidneys and removing excess glucose through urine. Unlike other diabetes treatments, it does not depend on a patient’s insulin levels to be effective.
European Union regulators had already approved the drug, also labeled empagliflozin, in May.
Earlier this year, Lilly and Boehringer said the FDA didn’t approve the drug because of concerns about the Boehringer factory in Germany where it will be made. But a Lilly spokeswoman said Friday those concerns have been resolved.
Boehringer developed the drug, and Lilly will help co-promote it. . . .
We will keep a weather eye on the horizon -- for this emerging battle. Off to see "Guardians of the Galaxy", now (middle son's call). Fingers crossed. Literally -- heh!
2 comments:
The "cut from the same cloth" verbiage proves that the person responsible for that quote has no idea how these therapies work. This product has a completely different MOA (mechanism of action) than Januvia. It will however compete directly with Invokana and Farxiga.
Thanks Anon. -- you are quite right that a SGLT2 inhibitor (like the new Lilly drug) works differently than a DPP-4 inhibitor (like Januvia).
True enough.
But (in my opinion) to think that the former will not compete for the same Type 2 patients as the latter -- seems slightly naive.
But I agree -- the method of action differs.
Do stop back -- Namaste
Post a Comment